Pre-Conference Workshop Day

Tuesday | August 17, 2021

Workshop A
Genomic & Phenotypic Tumour Heterogeneity in Prostate Cancer

Workshop B
Diversity in Prostate Cancer Clinical Trials

Workshop A:
Genomic & Phenotypic Tumour Heterogeneity in Prostate Cancer

9AM-12PM EST | 3PM-6PM CET

Prostate cancer is known to be a heterogeneous disease characterized by a high level of inter- and intratumoral diversity. This heterogeneity manifests itself at the genomic, epigenetic and phenotypic level and poses major challenges for diagnosis and treatment.

In this workshop, we provide a framework for assessing heterogeneity, highlight novel technologies and critically discuss the implications for clinical management and drug development.

Attending this workshop will enable you to:

  • Uncover broad/general concepts, recent findings and challenges of heterogeneity in Metastatic Castrate- Resistant Prostate Cancer (mCRPC)
  • Gain in-depth expertise in single cell analysis (New technologies, clinical diagnostic research questions - sequencing based assays)
  • Explore resistance mechanisms as they relate to and are driven by intra-tumor heterogeneity

Workshop Leaders:

Michael Haffner

Michael Haffner
Assistant Professor
Fred Hutchinson Cancer Research Center

John Lee

John Lee
Assistant Professor
Fred Hutchinson Cancer Research Center

Henry Long

Henry Long
Associate Director, Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute

Workshop B:
Diversity in Prostate Cancer Clinical Trials

1PM - 4PM EST | 7PM - 10PM CET

Prostate cancer (PCa) incidence and mortality rates in African American men are double that of any other race/ethnicity in the United States. Thorough understanding of the biological factors that contribute to this long-standing cancer health disparity (CHD) is required to improve the major public health concern and close this gap.

However, few models exist that can compare racially diverse specimens directly to evaluate impact of ancestry dependent factors on disease pathway selection and drug susceptibility.

Attending this workshop will enable you to:

  • Examine racially/ethnically diverse 3D PDX model of prostate cancer
  • Develop novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials

Workshop Leaders:

Daniel Harrington

Daniel Harrington
Assistant Professor
The University of Texas Health Science Center at Houston

Salma.Kaochar@bcm.edu

Salma Kaochar
Assistant Professor
Baylor College of Medicine